Objective To investigate the clinical efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT)and autologous hematopoietic stem cell transplantation(auto-HSCT)in treating patients with chronic phase chronic myeloid leukemia(CP-CML).Methods Clinical data of 80 CP-CML patients who underwent allo-HSCT or auto-HSCT at a tertiary hospital from September 2021 to September 2023 were retrospectively analyzed.According to the transplantation method,patients were divided into allo-HSCT group(n=40)and auto-HSCT group(n=40).The hematopoietic reconstitution time,transfusion requirements,early infection rate,1-year relapse incidence(RI),non-relapse mortality(NRM),and 1-year overall survival(OS)between the two groups were compared.Results The median time to neutrophil and platelet engraftment was shorter in the allo-HSCT group than in the auto-HSCT group(P＜0.05).The total transfusion amount and early infection rate were lower in the allo-HSCT group(P＜0.05).The 1-year RI in the allo-HSCT group(20.0%)was lower than that in the auto-HSCT group(50.0%)(P＜0.05),but the 1-year NRM(15.0%)was higher than that in the auto-HSCT group(5.0%)(P＜0.05).The 1-year OS in the allo-HSCT group(75.0%)was significantly higher than that in the auto-HSCT group(52.5%)(P＜0.05).Conclusion Compared with auto-HSCT,allo-HSCT can achieve faster hematopoietic reconstitution,reduce transfusion requirements and early infection risk,but carries a certain risk of transplant-related complications.Although allo-HSCT can significantly reduce RI,it also increases NRM.Overall,provide a higher OS than auto-HSCT and is an effective treatment for CP-CML.
维普
万方数据